55 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
28523115	59	Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP	Novartis Institutes For Biomedical Research
28169162	86	Discovery of AAT-008, a novel, potent, and selective prostaglandin EP4 receptor antagonist.	Askat
28105284	55	Discovery of Novel Seven-Membered Prostacyclin Analogues as Potent and Selective Prostaglandin FP and EP3 Dual Agonists.	Ono Pharmaceutical
26985320	89	Discovery of G Protein-Biased EP2 Receptor Agonists.	Ono Pharmaceutical
27133594	6	Piperidine derivatives as nonprostanoid IP receptor agonists 2.	Toray Industries
26996371	27	Piperidine derivatives as nonprostanoid IP receptor agonists.	Toray Industries
27055938	82	Structural optimization and structure-functional selectivity relationship studies of G protein-biased EP2 receptor agonists.	Ono Pharmaceutical
24021582	52	Discovery and characterization of NVP-QAV680, a potent and selective CRTh2 receptor antagonist suitable for clinical testing in allergic diseases.	Novartis Institutes For Biomedical Research
17236765	6	Identification of novel glycine sulfonamide antagonists for the EP1 receptor.	Glaxosmithkline
24900213	25	Novel 3-Oxazolidinedione-6-aryl-pyridinones as Potent, Selective, and Orally Active EP3 Receptor Antagonists.	TBA
18359630	37	Identification of prostaglandin D2 receptor antagonists based on a tetrahydropyridoindole scaffold.	Merck Frosst Canada
18291643	76	Structure-activity relationships and pharmacokinetic parameters of quinoline acylsulfonamides as potent and selective antagonists of the EP(4) receptor.	Merck Frosst Centre For Therapeutic Research
16931013	138	Comparison between two classes of selective EP(3) antagonists and their biological activities.	Merck Frosst Centre For Therapeutic Research
15914004	34	Discovery of diphenylcarbamate derivatives as highly potent and selective IP receptor agonists: orally active prostacyclin mimetics. Part 3.	Fujisawa Pharmaceutical
15357985	34	AL-12182, a novel 11-oxa prostaglandin analog with topical ocular hypotensive activity in the monkey.	Alcon Research
2909739	17	Prostaglandin photoaffinity probes: synthesis and biological activity of azide-substituted 16-phenoxy- and 17-phenyl-PGF2 alpha prostaglandins.	University of Kentucky
12643927	164	Discovery of a potent and selective agonist of the prostaglandin EP4 receptor.	Merck Frosst Centre For Therapeutic Research
21208803	81	The identification of substituted benzothiophene derivatives as PGE(2) subtype 4 receptor antagonists: From acid to non-acid.	Merck Frosst Centre For Therapeutic Research
21036609	38	Potent and highly selective DP1 antagonists with 2,3,4,9-tetrahydro-1H-carbazole as pharmacophore.	Merck Frosst Centre For Therapeutic Research
20926294	65	3-Urea-1-(phenylmethyl)-pyridones as novel, potent, and selective EP3 receptor antagonists.	Glaxosmithkline
20471829	43	Discovery of 4-[1-[([1-[4-(trifluoromethyl)benzyl]-1H-indol-7-yl]carbonyl)amino]cyclopropyl]benzoic acid (MF-766), a highly potent and selective EP4 antagonist for treating inflammatory pain.	Merck Frosst Canada
20303752	143	1,7-Disubstituted oxyindoles are potent and selective EP(3) receptor antagonists.	Decode Chemistry
19836233	31	Heterocyclic 1,7-disubstituted indole sulfonamides are potent and selective human EP3 receptor antagonists.	Decode Chemistry
20163116	116	The discovery of 4-{1-[({2,5-dimethyl-4-[4-(trifluoromethyl)benzyl]-3-thienyl}carbonyl)amino]cyclopropyl}benzoic acid (MK-2894), a potent and selective prostaglandin E2 subtype 4 receptor antagonist.	Merck Frosst Centre For Therapeutic Research
19592244	61	7-Azaindole-3-acetic acid derivatives: potent and selective CRTh2 receptor antagonists.	Novartis Institutes of Biomedical Research
19487124	39	Discovery of novel aminothiadiazole amides as selective EP(3) receptor antagonists.	Glaxosmithkline
19332369	43	Discovery of sodium 6-[(5-chloro-2-{[(4-chloro-2-fluorophenyl)methyl]oxy}phenyl)methyl]-2-pyridinecarboxylate (GSK269984A) an EP(1) receptor antagonist for the treatment of inflammatory pain.	Glaxosmithkline
19307115	89	Discovery of potent and selective DP1 receptor antagonists in the azaindole series.	Merck Frosst Centre For Therapeutic Research
19188065	116	3-Acrylamide-4-aryloxyindoles: synthesis, biological evaluation and metabolic stability of potent and selective EP3 receptor antagonists.	Decode Chemistry
19121942	57	Peri-substituted hexahydro-indolones as novel, potent and selective human EP3 receptor antagonists.	Decode Chemistry
19036582	45	Discovery of GSK345931A: An EP(1) receptor antagonist with efficacy in preclinical models of inflammatory pain.	Glaxosmithkline
18701276	97	Highly functionalized 7-azaindoles as selective PPAR gamma modulators.	Merck Research Laboratories
17300164	62	Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]-acetic acid (MK-0524).	Merck Frosst Canada
16529930	96	Identification of an indole series of prostaglandin D2 receptor antagonists.	Merck Frosst Canada
15935659	17	Metabolism investigation leading to novel drug design: orally active prostacyclin mimetics. Part 4.	Fujisawa Pharmaceutical
15857112	55	Discovery of diphenyloxazole and Ndelta-Z-ornithine derivatives as highly potent and selective human prostaglandin EP(4) receptor antagonists.	Fujisawa Pharmaceutical
14552786	88	Structure-activity relationship of triaryl propionic acid analogues on the human EP3 prostanoid receptor.	Merck Frosst Centre For Therapeutic Research
12182865	88	Structure-activity relationship of biaryl acylsulfonamide analogues on the human EP(3) prostanoid receptor.	Merck Frosst Centre For Therapeutic Research
11708917	33	Synthesis and biological evaluation of prostaglandin-F alkylphosphinic acid derivatives as bone anabolic agents for the treatment of osteoporosis.	Procter & Gamble Pharmaceuticals
11266183	32	Structure-activity relationship on the human EP3 prostanoid receptor by use of solid-support chemistry.	Merck Frosst Canada
10978187	4	Synthesis and biological activity of a novel 11a-homo (cyclohexyl) prostaglandin.	Alcon Laboratories
10915040	84	Synthesis and in vitro evaluation of human FP-receptor selective prostaglandin analogues.	Procter & Gamble Pharmaceuticals
10715159	112	Design and synthesis of 13,14-dihydro prostaglandin F(1alpha) analogues as potent and selective ligands for the human FP receptor.	Procter and Gamble Pharmaceuticals
10509919	103	New class of biphenylene dibenzazocinones as potent ligands for the human EP1 prostanoid receptor.	Merck Frosst Centre For Therapeutic Research
29636218	43	Discovery of {4-[4,9-bis(ethyloxy)-1-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl]-2-fluorophenyl}acetic acid (GSK726701A), a novel EP	Glaxosmithkline
19317450	23	Identification and characterization of small molecule inhibitors of a class I histone deacetylase from Plasmodium falciparum.	Harvard Medical School
17824679	53	Novel 2,7-Dialkyl-Substituted 5(S)-Amino-4(S)-hydroxy-8-phenyl-octanecarboxamide Transition State Peptidomimetics Are Potent and Orally Active Inhibitors of Human Renin.	Novartis Pharmaceuticals
8057276	11	Crystal-structure-based design and synthesis of novel C-terminal inhibitors of HIV protease.	Agouron Pharmaceuticals